Society for Translational Oncology (STO) Release: 2012 Chabner Colloquium Highlights Collaboration in Cancer Treatment Studies  
10/9/2012 12:12:58 PM

Durham, NC – The Society for Translational Oncology (STO) has announced that registration is now open for the 2012 Chabner Colloquium, presenting updates on promising targets for development of new cancer treatments. The continuing medical education (CME) symposium is jointly sponsored by The Massachusetts General Hospital Cancer Center and STO, in partnership with The Oncologist, STO's official journal.

The meeting will be held November 5-6, 2012, at The Liberty Hotel in Boston. Clinicians, researchers, industry professionals, and others interested in learning about advances in cancer biology leading to new approaches in clinical practice are invited to register online at

Offered for the third year, the 2012 Chabner Colloquium includes presentations on emerging molecular and genetic targets for cancer treatments—with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. research centers will provide informative updates on their work.

The program includes updates in four key areas of basic science research with implications for cancer treatment:

• "Modifiers of Gene Expression" will be an informative update on genetic factors affecting individual responses to cancer treatment.

• "Signaling inhibitors: Insights into Resistance" will focus on new discoveries on the molecular basis of cancer treatment resistance.

• "Tumor Quiescence, Drug Response in Vitro, and Drug Resistance" will cover new therapies targeting quiescent cancer cells.

• "New Clinical Breakthroughs in Cancer Treatment" includes innovations in lung cancer, chronic myelogenous leukemia (CML), "smart" T-cell vaccines, exosomes, and anti-PD1.

The program also includes a Monday afternoon forum with junior faculty members from Dana-Farber/Harvard Cancer Center, followed by an evening reception.

The meeting is named for Dr Bruce A. Chabner, Director of Clinical Research at Massachusetts General, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr Chabner designs and leads this annual program. "Our 2012 program will report on genetic and epigenetic modifiers of gene expression," comments Dr Chabner. "It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."

STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This day and a half symposium will be designated for a maximum of 10 AMA PRA Category 1 Credit(s)™.

For more information go to or contact STO at (919) 433-0489 or

About the Society for Translational Oncology

STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit:

About The Oncologist

Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its eighteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit:

About The Massachusetts General Hospital Cancer Center

A Comprehensive Cancer Center

An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.

U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital's exceptional nursing care.

Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.

The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.

The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine. For more information, visit:

For more information, contact:

Gabby Cruze, Executive Director, STO

(919) 433-0489